Can something as simple as a cup of coffee with milk have an anti-inflammatory effect in humans? Apparently so, according to a new study from the University of Copenhagen.
Irvine, Calif., Jan. 30, 2023 — Combating Alzheimer’s and other neurodegenerative diseases by inserting healthy new immune cells into the brain has taken a leap toward reality. Neuroscientists at the University of California, Irvine and the University of Pennsylvania have found a way to safely thwart the brain’s resistance to them, vaulting a key hurdle in the quest.
Investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that a subset of mutations within the overall TMB, termed “persistent mutations,” are less likely to be edited out as cancer evolves, rendering tumors continuously visible to the immune system and predisposing them to respond to immunotherapy.
A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.
A new COVID-19 vaccine based on a different platform than current vaccines on the market has been tested in humans for the first time by researchers at Radboud university medical center.
The Wistar Institute, which has recently launched a $75 million programmatic campaign investing in biomedical advances, announces the appointment of Michael Criscuolo as Vice President of Development.
Female lymphoma patients undergoing the morning chemotherapy treatment show a lower survival probability than those undergoing the afternoon treatment.
Spring allergy symptoms will start to appear soon in parts of the country. Many allergists advise their patients to set a reminder for Valentine’s Day to start taking allergy medications.
An international consortium co-led by Vanderbilt University Medical Center immunogeneticist Rubén Martínez-Barricarte, PhD, has discovered a new genetic disorder that causes immunodeficiency and profound susceptibility to opportunistic infections including a life-threatening fungal pneumonia. The discovery, reported Jan. 20 in the journal Science Immunology, will help identify people who carry this in-born error of immunity (IEI).
A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, according to a Dana-Farber Cancer Institute researcher.
In a brightly lit kitchen one recent afternoon, cancer survivors Patricia Rhodes and Evette Knight were part of a group gathered around a convection burner and a sauté pan filled with mushrooms. Cancer dietitian Meghan Laszlo, RD, explained why they shouldn’t stir quite yet. “We’re going to try our best to leave them alone so that they brown,” she said.
amfAR, The Foundation for AIDS Research, has awarded Luis J. Montaner, D.V.M., D.Phil., in collaboration with Mohamed Abdel-Mohsen, Ph.D., a Target Grant for $397,663 over two years.
Researchers are building detailed maps of colorectal cancer to better understand the dynamics of the disease
Researchers from the University of Michigan Rogel Cancer Center have found a mechanism for why a subset of patients’ tumors grow, rather than shrink, when faced with immunotherapy.
New UCLA-led research suggests that antiretroviral drugs called TAF and TDF directly reduce energy production by mitochondria, structures inside cells that generate the power that cells use to function. Both drugs led to reduced cellular oxygen consumption rates, a measure of the ability of the mitochondria to produce energy, compared with controls.
People with HIV have a higher chance of having chronic systemic inflammation during pregnancy, according to a Rutgers study.
A tendency for one or both spouses to avoid or withdraw from tough conversations could set up married couples for emotional distress, bad feelings about their relationship, chronic inflammation and lowered immune function, new research suggests.
A new study led by scientists at La Jolla Institute for Immunology (LJI) shows how ideal antibodies against SARS-CoV-2 hit their marks. Now scientists are looking at how we might harness their power in new antibody therapeutics and even more effective COVID-19 vaccines.
Also evokes central and peripheral pro-inflammatory responses
The researchers screened a library of drugs using a mouse endothelial cell line to identify pathways that are involved in the regulation of Robo4 and found that two competitive SMAD signaling pathways appear to regulate Robo4 expression. When the researchers treated LPS-injected mice with a drug that inhibits ALK1-SMAD signaling, they observed increased Robo4 expression, decreased vascular permeability, and reduced mortality.
High levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months. Omicron infection generates durable mucosal antibodies, reducing the risk of re-infection.
NEW YORK, NY – Jan. 17, 2023 – The American Thoracic Society is starting the new year poised to improve vaccination rates with three health system partners: University of Arizona/ Banner Health; West Virginia University Hospitals, Inc.; and San Francisco Health Network/ University of California.
Jennifer Wargo, M.D., professor of Surgical Oncology and Genomic Medicine at The University of Texas MD Anderson Cancer Center, has received a 2023 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST) for her contributions to the understanding of how the gut microbiome influences responses to immunotherapy and other cancer treatments.
Scientists from the Institut Pasteur, Université Paris Cité, the CNRS and the Collège de France have used paleogenomics to trace 10,000 years of human immune system evolution.
Gut bacteria can influence brain health, according to a study of mice genetically predisposed to develop Alzheimer’s-like brain damage. The study, by researchers at Washington University School of Medicine in St. Louis, indicates that gut bacteria produce compounds that influence the behavior of immune cells, including ones in the brain that can cause neurodegeneration. The findings suggest a new approach to treating Alzheimer’s and other neurodegenerative diseases.
Morteza Mahmoudi, an assistant professor in MSU’s Department of Radiology, explains why addressing disagreements with stronger standards will help ensure future nanomedicines are safe, effective and successful.
LA JOLLA, CA — Researchers at La Jolla Institute for Immunology (LJI) have at last uncovered how an enzyme called O-GlcNAc transferase (OGT) keeps cells healthy. Their findings, published in the Proceedings of the National Academies of Sciences, reveals a key aspect of cellular biology and may lead to important medical advances.
A team of researchers led by The University of Texas MD Anderson Cancer Center has developed a novel delivery system for messenger RNA (mRNA) using extracellular vesicles (EVs). The new technique has the potential to overcome many of the delivery hurdles faced by other promising mRNA therapies.
Findings from a newly published study provide further evidence suggesting that the breast milk of those vaccinated against COVID-19 may help protect babies from the illness
Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors.
New research in JNCCN finds that immunotherapy from immune checkpoint (PD-1) inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
CAR T cell therapy may enhance the effectiveness of surgery for solid tumors, according to a preclinical study from researchers in the Perelman School of Medicine at the University of Pennsylvania.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
A team of researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen has gained new insights into the maturation of SARS-CoV-specific antibodies after multiple vaccinations with the mRNA vaccine Comirnaty.
Hepatitis B virus (HBV) infections remain a major global health problem – according to the World Health Organization (WHO) there are around 300 million HBV carriers worldwide. Current treatments rarely succeed in curing the infection.
A new analysis by Cedars-Sinai investigators is furthering the scientific community’s understanding of COVID-19 immunity by showing that similar levels of COVID-19 antibodies are reached over an extended period of time in different population groups.
RUDN neurosurgeons studied the immune response in polytrauma - multiple serious traumatic lesions. The results will help specialists understand the features of the recovery period and adjust the treatment.
UBC researchers have identified three compounds that prevent COVID-19 infection in human cells, derived from natural sources including a B.C. sea sponge.
Christian Bréchot, MD, PhD, President of the Global Virus Network (GVN), Associate Vice President for International Partnerships and Innovation at the University of South Florida and Professor of the Division of Infectious Disease, Department of Internal Medicine at USF Health Morsani College of Medicine, the GVN Southeast U.S. Regional Headquarters today issued a statement on the surge of SARS-CoV-2.
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Sarcomas are cancer tumours found in e.g. the bones, muscles or fatty tissue. It is a rare type of cancer seen in only one per cent of cancer patients. It is complex and difficult to treat.
A new study led by Luís Graça, group leader at the Instituto de Medicina Molecular João Lobo Antunes (iMM, Lisbon) and full professor at the Medical School of the University of Lisbon, and Manuel Carmo Gomes, associate professor with aggregation at the Faculty of Sciences of the University of Lisbon (Ciências ULisboa), both members of the Direção Geral de Saúde (DGS) Technical Committee for Vaccination against COVID-19 (CTVC), and published today in the scientific journal Lancet Infectious Diseases*, shows that the protection conferred by hybrid immunity against the SARS-CoV-2 subvariant omicron BA.5, obtained by the infection of vaccinated people, lasts for at least eight months after the first infection.
A Ludwig Cancer Research study has discovered that the immune system’s surveillance of cancer can itself induce metabolic adaptations in the cells of early-stage tumors that simultaneously promote their growth and equip them to suppress lethal immune responses.
Peter Heeger, MD, Justin Steggerda, MD, Hirsh Trivedi, MD, and Lorenzo Zaffiri, MD, PhD, have all recently joined the Cedars-Sinai Comprehensive Transplant Center.
The long-term effects of infection on the immune system have long intrigued John Tsang, a Yale immunobiologist. After the body has faced down a pathogen, does the immune system return to the previous baseline? Or does a single infection change it in ways that alter how it will respond not only to a familiar virus but also to the next new viral or bacterial threat it faces?
Risk of severe COVID-19 continues to outweigh rare risk of post-vaccination myocarditis
Researchers from Rutgers Cancer Institute of New Jersey, the state’s leading cancer program and only National Cancer Institute-designated Comprehensive Cancer Center, together with RWJBarnabas Health, in collaboration with investigators from MD Anderson Cancer Center, discovered a novel triple immunotherapy combination, targeting checkpoints on both T cells and myeloid suppressor cells, that dramatically improved anti-tumor responses by reprogramming the tumor microenvironment in preclinical models of PDAC.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
